Value and significance of tumor markers as CEA,CA125,SCC-Ag,CA199 and CYFRA21-1 in the diagnosis of cervical cancer

Objective: To investigate the value and significance of serum CEA, CA125, SCC-Ag, CA199 and CYFRA21-1 in the diagnosis of cervical cancer by comparing the detection of five serum markers. Methods: A total of 108 cases were divided into three groups, including 60 cervical cancerpatients and 20 cervical intraepithelial neoplasiain patients treated in our hospital from September 2015 to September 2016 and 28 healthy women. Radioimmunoassay was used to detect and compare the serum levels of CA125, CA199, CYFRA21-1 and ELISA method was used to detect and compare the serum levels of SCC-Ag, CEA. Results: (1) There was no statistically significant difference in the serum CEA, CA125, SCC-Ag, CA199, CYFRA21-1 levels between CIN group and control group. The serums CEA, CA125, SCC-Ag, CA199, CYFRA21-1 levels of cervical cancer patients were significantly higher than the other two groups. The differences were statistically significant. (2)There were statistically significant differences in the serum CEA, CA125, SCC-Ag, CA199, CYFRA21-1 levels between different cervical pathological type groups.The serum CA125, CA199, CEA levels of cervical glandular cancer patients were significantly higher than the other two groups. The differences were statistically significant. The serum SCC-Ag, CYFRA21-1 levels of cervical squamous cancer patients were significantly higher than the other two groups. The differences were statistically significant. Conclusion: The serums CEA, CA125, SCC-Ag, CA199, CYFRA21-1 levels of cervical cancer patients were significantly higher than cervical intraepithelial neoplasiain patients and healthy women. The serum CA125, CA199, CEA levels of cervical glandular cancer patients were significantly higher and the serum SCC-Ag, CYFRA21-1 levels of cervical squamous cancer patients were significantly higher. The five tumor markers can be used in diagnosis of cervical cancer and they are also worthy in distinguishing cervical pathological types.

Clinical efficacy and effect on serum HE4, SMRP, CA125, CA199, B7-H4, TPS of carboplatin combined with paclitaxel for patients with ovarian cancer

Objective:To study the clinical efficacy and effect on serum HE4, SMRP, CA125, CA199, B7-H4, TPS of carboplatin combined with paclitaxel for patients with ovarian cancer.Methods:A total of 80 patients with ovarian cancer in our hospital from December 2014 to December 2016 were enrolled in this study. The subjects were divided into the control group (n=40) and the treatment group (n=40) randomly. The control group was treated with carboplatin;the treatment group was treated with carboplatin combined with paclitaxel. 21 d for a period of treatment and the two groups were treated for 2 periods. The serum HE4, SMRP, CA125, CA199, B7-H4, TPS levels of the two groups before and after treatment was compared. Results:There were no significantly differences of the serum HE4, SMRP, CA125, CA199, B7-H4, TPS levels of the two groups before treatment. The serum HE4, SMRP, CA125, CA199, B7-H4, TPS levels of the two groups after treatment were significantly lower than before treatment, and that of the treatment group were significantly lower than that of the control group.Conclusion: Carboplatin combined with paclitaxe for patients with ovarian cancer can significantly reduce the serum HE4, SMRP, CA125, CA199, B7-H4, TPS levels;can be used for the prognosis of patients with ovarian cancer after treatment.